Market
ResMed completes $340m Noctrix Health acquisition
ResMed completed its acquisition of Noctrix Health for $340 million. Noctrix's lead product, Nidra, is a neuromodulation device targeting peroneal nerves to treat restless leg syndrome symptoms. The deal expands ResMed's portfolio in sleep and respiratory care.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network